MA24401A1 - Procede pour la preparation de pyridines substitues et intemediaires utilisees a cette fin - Google Patents

Procede pour la preparation de pyridines substitues et intemediaires utilisees a cette fin

Info

Publication number
MA24401A1
MA24401A1 MA24864A MA24864A MA24401A1 MA 24401 A1 MA24401 A1 MA 24401A1 MA 24864 A MA24864 A MA 24864A MA 24864 A MA24864 A MA 24864A MA 24401 A1 MA24401 A1 MA 24401A1
Authority
MA
Morocco
Prior art keywords
intemedary
substituted
preparation
pyridines used
pyridines
Prior art date
Application number
MA24864A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA24401A1 publication Critical patent/MA24401A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA24864A 1996-11-14 1997-11-11 Procede pour la preparation de pyridines substitues et intemediaires utilisees a cette fin MA24401A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3088096P 1996-11-14 1996-11-14

Publications (1)

Publication Number Publication Date
MA24401A1 true MA24401A1 (fr) 1998-07-01

Family

ID=21856496

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24864A MA24401A1 (fr) 1996-11-14 1997-11-11 Procede pour la preparation de pyridines substitues et intemediaires utilisees a cette fin

Country Status (32)

Country Link
US (1) US6291489B1 (fr)
EP (1) EP0938476B1 (fr)
JP (1) JP3510635B2 (fr)
KR (1) KR20000053314A (fr)
CN (1) CN1237160A (fr)
AP (1) AP805A (fr)
AR (1) AR010584A1 (fr)
AT (1) ATE319687T1 (fr)
AU (1) AU4634697A (fr)
BG (1) BG103393A (fr)
BR (1) BR9712951A (fr)
CA (1) CA2270386C (fr)
CO (1) CO4930261A1 (fr)
DE (1) DE69735433D1 (fr)
EA (1) EA199900375A1 (fr)
GT (1) GT199700118A (fr)
HR (1) HRP970612A2 (fr)
ID (1) ID18898A (fr)
IL (1) IL129688A0 (fr)
IS (1) IS5029A (fr)
MA (1) MA24401A1 (fr)
MY (1) MY132507A (fr)
NO (1) NO992296D0 (fr)
OA (1) OA11044A (fr)
PA (1) PA8441401A1 (fr)
PE (1) PE10299A1 (fr)
TN (1) TNSN97172A1 (fr)
TR (1) TR199901063T2 (fr)
UY (1) UY24774A1 (fr)
WO (1) WO1998021184A1 (fr)
YU (1) YU22099A (fr)
ZA (1) ZA9710186B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID26299A (id) * 1998-04-08 2000-12-14 Novartis Ag Herbisida baru
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
CA2362070A1 (fr) * 1999-02-16 2000-08-24 Masaru Mitsuda Derives d'acetylpyridine substituee et procede de preparation d'intermediaires pour agoniste du recepteur adrenergique .beta.3 optiquement actif, faisant appel a ces derives
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
DE60015036T2 (de) * 1999-07-23 2006-03-02 Pfizer Products Inc., Groton Zwischenprodukte und ein Verfahren zur Herstellung von beta3-Adrenergischer Rezeptor-Agoniste
US20040265991A1 (en) * 2001-10-17 2004-12-30 Naoaki Taoka Process for preparation of (s)-alpha-halomethylpyridine-methanol derivatives
WO2003072573A1 (fr) * 2002-02-27 2003-09-04 Pfizer Products Inc. Formes cristallines de (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
EP1478625A1 (fr) 2002-02-27 2004-11-24 Pfizer Products Inc. Procedes et intermediaires utiles dans la preparation d'agonistes du recepteur beta-3-adrenergique
EP1424079A1 (fr) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combinaison d'un agoniste du beta-3-récepteur et d'un inhibiteur de recaptage de sérotonine et/ou norépinéphrine
ATE406363T1 (de) 2003-05-09 2008-09-15 Hoffmann La Roche Methylindole und methylpyrrolopyridine als alpha- 1-adrenerge agonisten
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
US5019578A (en) 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
ATE154935T1 (de) 1993-06-14 1997-07-15 Pfizer Zweite amine als antidiabetische mittel und für die behandlung von fettleibigkeit
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
WO1996035670A1 (fr) * 1995-05-10 1996-11-14 Pfizer Inc. AGONISTES DU RECEPTEUR β-ADRENERGIQUE
JPH11504649A (ja) * 1995-05-10 1999-04-27 ファイザー・インコーポレーテッド β−アドレナリン作働性アゴニスト

Also Published As

Publication number Publication date
WO1998021184A1 (fr) 1998-05-22
OA11044A (en) 2002-02-20
ATE319687T1 (de) 2006-03-15
PE10299A1 (es) 1999-02-10
AP805A (en) 2000-01-28
ID18898A (id) 1998-05-20
AU4634697A (en) 1998-06-03
EP0938476A1 (fr) 1999-09-01
EA199900375A1 (ru) 1999-12-29
EP0938476B1 (fr) 2006-03-08
BR9712951A (pt) 1999-12-07
GT199700118A (es) 1999-05-05
AR010584A1 (es) 2000-06-28
US6291489B1 (en) 2001-09-18
CO4930261A1 (es) 2000-06-27
IL129688A0 (en) 2000-02-29
UY24774A1 (es) 1998-05-05
TR199901063T2 (xx) 1999-08-23
CN1237160A (zh) 1999-12-01
CA2270386C (fr) 2004-08-03
DE69735433D1 (de) 2006-05-04
JP3510635B2 (ja) 2004-03-29
AP9701147A0 (en) 1998-01-31
TNSN97172A1 (fr) 2005-03-15
MY132507A (en) 2007-10-31
ZA9710186B (en) 1999-05-12
HRP970612A2 (en) 1998-08-31
NO992296L (no) 1999-05-12
BG103393A (en) 2000-07-31
IS5029A (is) 1999-04-16
KR20000053314A (ko) 2000-08-25
CA2270386A1 (fr) 1998-05-22
JP2000504347A (ja) 2000-04-11
NO992296D0 (no) 1999-05-12
YU22099A (sh) 2001-09-28
PA8441401A1 (es) 2000-05-24

Similar Documents

Publication Publication Date Title
MA23611A1 (fr) Procede pour la synthese de sulfoxydes substitues
MA24426A1 (fr) Procede pour la preparation de nouveaux composes
EP0738424A4 (fr) Procede et structure de passivation pour circuit integre
HUT53358A (en) Process for producing leukotriene antagonist tetrazoles and intermediates thereof
MA20880A1 (fr) Procede pour la preparation de derives de thienoimidazole substitues
MA21983A1 (fr) Procede pour la preparation de derives de quinolone .
FR2654332B1 (fr) Appareillage pour stomie.
FR2687687B1 (fr) Procede pour mesurer la taille de fragments d'adn.
FR2781801B1 (fr) Procede pour la preparation de dianhydride pyromellique
RO96413A (fr) Procede pour la preparation des derives de thoadiazole
MA24319A1 (fr) Procedes et intermediaires pour la preparation de derives de chromanol substitues
MA23900A1 (fr) Procede pour la preparation de compositions antiretrovirale
FR2733227B1 (fr) Procede pour la preparation de 1,1-difluoroethane
FR2559771B1 (fr) Derives de la 3-pyrrolidinopropiophenone et procede pour leur preparation
FR2663173B1 (fr) Circuit d'attenuation et procede d'etalonnage pour ce circuit.
FI904680A7 (fi) Menetelmä ja laite folioiden "kylmäsyvävetämiseksi"
MA24245A1 (fr) Procede pour la preparation de nouveaux composes sulfonylures
FR2628421B1 (fr) Procede de preparation des derives de 1,4-dihydropyridine et nouveaux intermediaires utiles pour cette preparation
MA24078A1 (fr) Procede pour l'utilisation de derives de tetrahydroisoquinoleine
FR2731703B1 (fr) Procede pour la preparation de difluoromethane
FR2731365B1 (fr) Tensioactif glycolipidique et procede pour sa preparation
FR2728566B1 (fr) Procede de preparation de pentene-nitriles
FR2551079B1 (fr) Compositions perfectionnees pour la dissolution de metaux et procede de dissolution
FR2549042B1 (fr) Procede pour la preparation de la 3,11-dimethyl-2-nonacosanone
FR2574792B1 (fr) Procede pour la preparation de derives de pyrrolidine